Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | MAOA | P21397 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.54 |
| ▸ | GAA | P10253 | 4/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CA7 | P43166 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3178327 | 0.98 | LMNA (0.56) | LMNAMAOACYP1A2CYP3A4ALDH1A1 | |
| SCHEMBL2888716 | 0.87 | TSHR (0.60) | LMNAMAOACYP1A2CYP3A4ALDH1A1 | |
| SCHEMBL31041162 | 0.86 | LMNA (0.58) | LMNAMAOACYP1A2CYP3A4ALDH1A1 | |
| SCHEMBL11581128 | 0.86 | ALDH1A1 (0.64) | LMNAMAOACYP1A2CYP3A4ALDH1A1 | |
| SCHEMBL754826 | 0.86 | LMNA (0.62) | LMNAMAOACYP1A2CYP3A4ALDH1A1 | |
| SCHEMBL17979814 | 0.85 | ALDH1A1 (0.47) | LMNAMAOACYP1A2CYP3A4ALDH1A1 | |
| SCHEMBL635364 | 0.84 | CA12 (0.70) | LMNAMAOACYP1A2CYP3A4ALDH1A1 | |
| SCHEMBL194508 | 0.83 | CYP4F2 (0.63) | LMNAMAOACYP1A2CYP3A4ALDH1A1 | |
| SCHEMBL10668013 | 0.83 | TSHR (0.55) | LMNAMAOACYP1A2CYP3A4ALDH1A1 | |
| SCHEMBL1496445 | 0.83 | LMNA (0.54) | LMNAMAOACYP1A2CYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116730657-B | Cold patch asphalt mixture and preparation method thereof | 芜湖城瑞路桥建设有限公司 | 2024-07-12 | — | — | CN | claimed |
| CN-116730657-B | Cold patch asphalt mixture and preparation method thereof | 芜湖城瑞路桥建设有限公司 | 2024-07-12 | — | — | CN | disclosed |
| US-11826365-B2 | Type II raf kinase inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11826365-B2 | Type II raf kinase inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11826365-B2 | Type II raf kinase inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| CN-116730657-A | Cold patch asphalt mixture and preparation method thereof | 芜湖城瑞路桥建设有限公司 | 2023-09-12 | — | — | CN | disclosed |
| US-20200297721-A1 | TYPE II RAF KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-09-24 | — | — | US | disclosed |
| US-20200297721-A1 | TYPE II RAF KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-09-24 | — | — | US | disclosed |
| EP-2937345-B1 | TYPE II RAF KINASE INHIBITORS | DANA FARBER CANCER INST INC (US) | 2018-03-21 | — | — | EP | disclosed |
| EP-2937345-B1 | TYPE II RAF KINASE INHIBITORS | DANA FARBER CANCER INST INC (US) | 2018-03-21 | — | — | EP | disclosed |
| EP-1751131-A1 | MTP INHIBITING ARYL PIPERIDINES OR PIPERAZINES SUBSTITUTED WITH 5-MEMBERED HETEROCYCLES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-14 | — | — | EP | disclosed |
| EP-1697319-A1 | PYRROLE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-09-06 | — | — | EP | disclosed |
| EP-1670763-A1 | CYCLOPENTENE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-06-21 | — | — | EP | disclosed |
| US-20050239802-A1 | (2-((2-alkoxy)-phenyl)-cyclopent-1enyl) aromatic carbo and heterocyclic acid and derivatives | GLAXO GROUP LIMITED (GB) | 2005-10-27 | — | — | US | disclosed |
| WO-2005085226-A1 | MTP INHIBITING ARYL PIPERIDINES OR PIPERAZINES SUBSTITUTED WITH 5-MEMBERED HETEROCYCLES | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-09-15 | — | — | WO | disclosed |
| CN-1659131-A | (2-((2-alkoxy) -phenyl) -cyclopent-1-enyl) aromatic carbo and heterocyclic acid and derivatives | GLAXO GROUP LTD (GB) | 2005-08-24 | — | — | CN | disclosed |
| WO-2005054191-A1 | PYRROLE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2005-06-16 | — | — | WO | disclosed |
| WO-2005037793-A1 | CYCLOPENTENE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2005-04-28 | — | — | WO | disclosed |
| US-6103720-A | ENZYME INHIBITORS; ANTIICHEMIC AND -TUMOR AGENTS; STROKES; ALZEIMER'S DISEASE | BASF AKTIENGESELLSCHAFT (DE) | 2000-08-15 | — | — | US | disclosed |
| CN-1245486-A | Ketobenzamides as calpain inhibitors | BASF AG (DE) | 2000-02-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239802-A1 | (2-((2-alkoxy)-phenyl)-cyclopent-1enyl) aromatic carbo and heterocyclic acid and derivatives | CYP2C9, CYP2C19, CNR1 | LMNA 1439/4885MAOA 562/4885CYP1A2 11/4885 |
| US-11826365-B2 | Type II raf kinase inhibitors | BRAF, RAF1, ARAF | LMNA 3146/4885MAOA 3839/4885CYP1A2 3401/4885 |
| US-20200297721-A1 | TYPE II RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | LMNA 3146/4885MAOA 3839/4885CYP1A2 3401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.